R. Mani

发表

Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats

J. Byrd, S. Kulp, Dasheng Wang, 2020, The AAPS Journal.

OSU‐DY7, a novel D‐tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen‐activated protein kinase pathway

J. Byrd, S. Kulp, C. Chen, 2011, British journal of haematology.

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

P. Ettmayer, S. Carotta, M. Kerenyi, 2020, Molecular Cancer Therapeutics.

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Logan A. Walker, J. Byrd, R. Bundschuh, 2021, Blood.

Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A

Chi Wang, D. S. St. Clair, H. Geiger, 2017, Oncotarget.

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

J. Byrd, C. Chen, R. Baiocchi, 2011, Blood.

FTY 720 increases CD 74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

J. Byrd, C. Chen, M. Prætorius-Ibba, 2011 .

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia

I. Waizenegger, K. Heider, X. Mo, 2018, Oncotarget.

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD 33 antibody BI 836858 in acute myeloid leukemia

I. Waizenegger, K. Heider, X. Mo, 2022 .

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Michael A. Freitas, Jeffrey A Jones, J. Byrd, 2012, Cancer cell.

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

J. Byrd, C. Chen, R. Baiocchi, 2010, Clinical Cancer Research.

FTY 720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D 1 and Phospho-Akt in Mantle Cell Lymphoma

J. Byrd, C. Chen, R. Baiocchi, 2010 .

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

M. Grever, A. Kinghorn, D. Jarjoura, 2012, Clinical Cancer Research.

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.

J. Byrd, X. Mo, Haiyong Peng, 2021, Blood advances.

ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

J. Byrd, L. J. Lee, C. Chen, 2015, Experimental Hematology.

Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.

J. Byrd, X. Mo, N. Muthusamy, 2020, Cytotherapy.

MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia

G. Wertheim, S. Blacklow, W. Pear, 2017, Science Signaling.

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

J. Byrd, V. Rangnekar, Chi Wang, 2018, Blood.

in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target

J. Byrd, A. Johnson, D. Lucas, 2013 .

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Yuh Min Chook, David Lucas, J. Byrd, 2012, Blood.

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in CLL mouse model.

Logan A. Walker, J. Byrd, L. J. Lee, 2019, Blood.

Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, L. J. Lee, 2014, Leukemia.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

M. Caligiuri, G. Lozanski, K. Heider, 2016, Blood.

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

J. Byrd, V. Rangnekar, X. Mo, 2019, Blood advances.

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

J. Byrd, G. Lozanski, C. Brooks, 2018, Haematologica.

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

J. Byrd, M. Phelps, X. Mo, 2017, Veterinary and comparative oncology.